Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIE trial of individualized immunotherapy in early-stage unfavorable classical Hodgkin lymphoma
2022-500571-32-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, doxorubicin, dacarbazine and vinblastine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University of Cologne. Primary endpoint: 1-year progression-free survival estimate. Planned start May 2024; status: authorised.
02
Drugs
tislelizumabdoxorubicindacarbazinevinblastine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-500571-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500571-32-00.